



(51) International Patent Classification:

C07D 487/14 (2006.01) *A61P 27/16* (2006.01)
C07D 471/14 (2006.01) *A61P 35/00* (2006.01)
A61K 31/55 (2006.01)

(21) International Application Number:

PCT/US2016/040612

(22) International Filing Date:

1 July 2016 (01.07.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/189,393 7 July 2015 (07.07.2015) US

(71) Applicants: ELI LILLY AND COMPANY [US/US];

Lilly Corporate Center, Indianapolis, Indiana 46285 (US).
 AUDION THERAPEUTICS [NL/NL]; Linneausparkweg
 10-2, 1098 EA Amsterdam (NL).

(72) Inventors: CLAY, Julia Marie; c/o Eli Lilly and Com-

pany, P.O. Box 6288, Indianapolis, Indiana 46206-6288
 (US). EDGE, Albert; c/o AUDION THERAPEUTICS,
 Linneausparkweg 10-2, 1098 EA Amsterdam (NL). HIPS-
 KIND, Philip Arthur; c/o Eli Lilly and Company, P.O.
 Box 6288, Indianapolis, Indiana 46206-6288 (US). GILL,
 John C.; c/o AUDION THERAPEUTICS, Linneauspark-
 weg 10-2, 1098 EA Amsterdam (NL). PATEL, Bharvin
 Kumar; c/o Eli Lilly and Company, P.O. Box 6288, Indi-
 anapolis, Indiana 46206-6288 (US). VAN ES, Helmuth
 Hendrikus Gerardus; c/o AUDION THERAPEUTICS,
 Linneausparkweg 10-2, 1098 EA Amsterdam (NL).
 WROBLESKI, Aaron D.; c/o Eli Lilly and Company,
 P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

ZHAO, Gaiying; c/o Eli Lilly and Company, P.O. Box
 6288, Indianapolis, Indiana 46206-6288 (US).

(74) Agents: **DEMETER, John C.** et al.; Eli Lilly and Com-
 pany, P.O. Box 6288, Indianapolis, Indiana 46206-6288
 (US).

(81) Designated States (unless otherwise indicated, for every
 kind of national protection available): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
 BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
 PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
 SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.



(84) Designated States (unless otherwise indicated, for every
 kind of regional protection available): ARIPO (BW, GH,
 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
 TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
 TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
 LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
 SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
 GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

[Continued on next page]

(54) Title: NOTCH PATHWAY SIGNALING INHIBITOR COMPOUNDS



(57) Abstract: The present invention provides the following compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing said compounds useful as a Notch pathway signaling inhibitor for the treatment of named cancers, sensorineural hearing loss caused by auditory hair cell loss, and inducing auditory hair cell generation.

Published:

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))